Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials
- 5 April 2011
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 27 (6) , 1263-1271
Abstract
(2011). Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Current Medical Research and Opinion: Vol. 27, No. 6, pp. 1263-1271. doi: 10.1185/03007995.2011.576238Keywords
This publication has 17 references indexed in Scilit:
- First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinibJournal of Hematology & Oncology, 2010
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity StudyJournal of Clinical Oncology, 2010
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNetJournal of Clinical Oncology, 2009
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side EffectsCurrent Drug Metabolism, 2009
- Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemiaNature Reviews Cancer, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003